At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 32 enrolled
Drug / intervention
LY2189265 +4 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
The Effect of LY2189265 on Insulin Secretion in Response to Intravenous Glucose Infusion
In Brief
A Phase 1 clinical trial evaluating LY2189265, Placebo, and 3 other interventions for Diabetes Mellitus, Type 2. Completed, enrolled 32 participants across 1 site.
Detailed Summary
The purpose of this study is to measure the effect of LY2189265 to increase insulin levels in response to glucose intake.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes Mellitus, Type 2
CountriesGermany
Collaborators--
Timeline
Phase 1CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartFeb 2011
First PostedFeb 2011
Primary CompletionAug 2011
TodayJul 2026
First PostedFeb 21, 2011
Enrollment StartFeb 1, 2011
Primary CompletionAug 1, 2011
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 15.4 years ago
Interventions
LY2189265biological
Administered subcutaneously
Placebodrug
Administered subcutaneously
Insulindrug
Administered intravenously
Glucosedrug
Administered intravenously
Glucagondrug
Administered intravenously